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Abstract: Aspirin is among the most commonly used pharmaceutical products used for the
management of fever, to relieve mild to moderate pain, to reduce swelling in inflammatory
conditions such as arthritis, while a low dose aspirin is used to prevent blood clots. The latter
effect reduces the risk of stroke and heart attack. However, its use is associated with
gastrointestinal and other complications. The aim of this study was to evaluate the influence of
aspirin in bleeding ulcers. 122 patients were included in this prospective comparative study that
were divided in two groups: the first group consisting of 60 patients that were treated with low
dose Aspirin, and the second group consisting of 62 patients that were treated with low dose
aspirin and pantoprazole (a proton pump inhibitor). All the patients had positive history for
previous ulcer disease in whom bleeding ulcers were evaluated with endoscopic examinations
during 12 months of treatment. The mean age of the patients with bleeding ulcers in the study
was 60.4±14.3 years, of whom 68.8% were males and 31.2% were females. In the aspirin only
treated group, after 12 months of administration, bleeding ulcers were present in 11 patients
(18.3%) while in the group that were co-prescribed aspirin and pantoprazole were present only
in 3 (4.8%) patients. Findings from this study show that the prevalence of bleeding ulcers is
significantly higher in the group treated with aspirin as monotherapy compared to the group that
were co-prescribed aspirin and pantoprazole. Gastroprotection with proton pump inhibitors is
essential in patients with positive history of gastrointestinal ulcers in the past that need long-term
use of prophylactic low-dose aspirin.
Keywords: bleeding ulcers, aspirin, PPI

Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that reduce pain, decrease
fever, and in higher doses decrease inflammation. Side effects include an increased risk of
stomach ulcers, heart attacks and renal injury (1,2).
Most of the NSAIDs inhibit the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2)
activity, and thereby the synthesis of prostaglandins and thromboxanes. It is assumed that
inhibiting COX-2 leads to the anti-inflammatory, analgesic and antipyretic effects and that those
NSAIDs also inhibiting COX-1, particularly aspirin, may cause gastrointestinal bleeding and
ulcers in large doses (3). Aspirin, the only NSAID able to irreversibly inhibit COX-1, is also
indicated for inhibition of platelet aggregation. This is useful for the management of thrombosis
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and prevention of adverse cardiovascular events. Aspirin inhibits platelet aggregation by
inhibiting the action of thromboxane A2. An estimated 10–20% of NSAID patients experience
dyspepsia. In the 1990s high doses of prescription NSAIDs were associated with serious upper
gastrointestinal adverse events, including bleeding (4). The main adverse drug reactions (ADRs)
associated with NSAID use relate to direct and indirect irritation of the gastrointestinal (GI) tract.
NSAIDs cause a dual assault on the GI tract: the acidic molecules directly irritate the gastric
mucosa, while inhibition of COX-1 and COX-2 reduces the levels of protective prostaglandins.
Inhibition of prostaglandin synthesis in the GI tract causes increased gastric acid secretion,
diminishes bicarbonate secretion, diminishes mucus secretion and diminishes trophic features of
the epithelial mucosa. However, their use is associated with increased risk of gastrointestinal
(GI), renal and cardiovascular (CV) effects (5,6,7,8). Injury to the mucosa of the GI tract by
NSAIDs is very common and ranges from minor lesions such as petechia or erosions to more
serious (and also much less frequent) lesions such as ulcers, which can result in complications
such as bleeding, perforation or obstruction. Patients may eventually die as a consequence of
these complications (9).
Gastrointestinal lesions in NSAID or aspirin users are usually repaired rapidly through a process
called 'restitution'(10). This process occurs rapidly without the need of cell division but it requires
an undamaged basement membrane where healthy epithelial cells migrate. When damage does
not penetrate the muscularis mucosa, the repair can be achieved within 1–3 days and involves
cell proliferation and re-establishment of the glandular architecture. When an ulcer is formed
(when the defect penetrates to the submucosa), repair can take from weeks to months involving
re-establishment of the vasculature with new blood vessel growth. A number of growth factors
including EGF and VEGF are involved in the process of ulcer repair (11).

Aim of the study
The aim of this study was to evaluate the influence of aspirin in bleeding ulcers by comparing
the patients with gastrointestinal bleeding using aspirin 100 mg who concomitantly received a
proton pomp inhibitor (PPI) with those who did not receive a PPI.
Specific goals of this study were age groups, endoscopic findings and comparison of two groups
of patients who had used PPI drugs with those who did not take any drugs for gastroprotection.

Method and patients
122 patients were included in this prospective comparative study that were divided in two groups:
the first group consisting of 60 patients that were treated with low dose Aspirin, and the second
group consisting of 62 patients that were treated with low dose aspirin and pantoprazole (a proton
pump inhibitor). All the patients had positive history for previous ulcer disease in whom bleeding
ulcers were evaluated with endoscopic examinations during 12 months of treatment.

Material and methods
The study was carried out at the Clinic of Gastroenterology with Hepatology at the University
Clinical Center of Kosovo (UCCK) between January 2015 and December 2017. The study was
retrospective, while descriptive and analytical methods were also used. There were 122
hospitalized and outpatient patients that were enrolled in the study.
Inclusion criteria included: patients over 18 years of both sexes, those who used low dose aspirin
and PPI, as well as patients who used low dose Aspirin without a PPI. Clinical exams and
laboratory tests and gastroscopy were performed in all study subjects. Patients were treated with
modern protocols for bleeding ulcers to complete the healing process. Criteria for exclusion from

63

the study were patients who have refused gastroscopy, patients who did not tolerate endoscopic
examination due to cardio-respiratory pathologies as well as patients without medical reports. All
gastroscopic examinations were performed with gastroscopy as well as reports of endoscopic
diagnosis were analyzed. The statistical methods used were the index of structures, arithmetic
mean and chi square test. For the presentation of the results, tables and graphs were used.

Results
The average age of the patients with bleeding ulcers in the study was 60.4±14.3 years with age
interval from 25 to 80 years, of whom 68.8% were males and 31.2% were females. In the aspirin
only treated group, after 12 months of administration, bleeding ulcers were present in 11 patients
(18.3%). In this group, only two patients have been occasionally taking NSAIDs, during the study
period. While in the group that were co-prescribed aspirin and pantoprazole, bleeding ulcers
were present only in 3 (4.8%) patients (P<0.01). In this group only one patient has been taking
NSAID.
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Fig. 1 Comparison of bleeding by the groups.

Discussion
Our results from this retrospective study show the need to administer PPI at the same time with
the aspirin taken for cardiologic or other indications. Moreover, it was shown that bleeding ulcers
in the patients who receive aspirin in love dose were significantly higher compared to patients
who receive at the same time a PPI (18.3% vs. 4.3% and P<0.01).
Kawamura et al. evaluated 226 patients, of whom 14 (6.2%) were endoscopically diagnosed
with peptic ulcer, co-treatment with anticoagulants or proton pump inhibitors (PPIs) was
significantly associated with decreased risk for peptic ulcer, The use of PPIs reduces the risk of
developing gastric or duodenal ulcers in Japanese patients taking low dose aspirin without preexisting gastroduodenal ulcers (12).
Tamura and al. in their study evaluated the effect of the cessation of low dose aspirin before
endoscopy and concluded that a significant association between aspirin and gastroduodenal
ulcers. Moreover, patients having two or more of five factors [i.e. advanced age (≥75 ys),
anticoagulants, antiplatelet drugs, NSAIDs and corticosteroids] had a significantly higher
prevalence for a low dose aspirin-induced gastroduodenal ulcers. Peptic ulcer history, abdominal
symptoms and the summation of risk factors increased the risk for aspirin-induced
gastroduodenal ulcers. Antagonists of histamine 2 receptors (H2RAs) and PPIs were effective for
the prevention of aspirin-induced gastroduodenal ulcers (13).
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Pilotto et al. in their study included 676 elderly patients who were non-steroidal antiinflammatory drugs or aspirin users and 2435 non-users who consecutively underwent upper
gastrointestinal endoscopy. The use of non-steroidal anti-inflammatory drugs and/or aspirin as
well as antisecretory drugs (H2RAs and PPIs) was evaluated by a structured interview. Protonpump inhibitor treatment was associated with a reduced risk of peptic ulcer in both, acute and
chronic non-steroidal anti-inflammatory drugs/aspirin users. Conversely, concomitant treatment
with H2RAs was associated with a significantly higher risk of peptic ulcer both in acute and
chronic non-steroidal anti-inflammatory drugs/aspirin users than non-users. PPI treatment
resulted in an absolute risk reduction of peptic ulcer by 36.6% in acute and 34.6% in chronic nonsteroidal anti-inflammatory drugs/aspirin users. (14)
Lazzaroni et al. reported in their long-term prevention studies, that H2ARs significantly reduce
duodenal ulcer rates, but are ineffective in reducing gastric ulceration. Marked acid suppression
with proton pump inhibitors (omeprazole 20-40 mg, lansoprazole 30 mg daily) also appears to
be very effective in healing gastric and duodenal ulcers in patients continuing the harmful drug
as well. In long-term prevention studies, omeprazole (20 mg daily) and pantoprazole (40 mg
daily) have also been shown to reduce the risk of gastric and duodenal ulcers and non-steroidal
anti-inflammatory drug-related dyspepsia. (15)

Conclusions
Findings from this study show that the prevalence of bleeding ulcers is significantly higher in the
group treated with aspirin as monotherapy compared to the group that were co-prescribed aspirin
and pantoprazole.
Gastroprotection with proton pump inhibitors is essential in patients with positive history of
gastrointestinal ulcers in the past that need long-term use of prophylactic low-dose aspirin.
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